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1. Introduction 
The traditional distinction between preventive and curative medicine has probably served, 
among others, programmatic and educational purposes, but does not look so robust (and 
valid) when used to back-up choices for innovative technologies or justify managerial 
economic options. Obviously, the line between both some secondary or tertiary preventive 
actions and many curative ones is often void, and above all a simple question of optical 
perspective. 
Indeed, in our opinion, prevention and precaution are the underlying humanistic driving 
forces that have, or should have, always presided to the management of health risks. And 
this should remain untouched. Is this merely an ideological choice? In any case, the 
implementation of these concepts is also definitely not detrimental to long term economical 
considerations, another real asset, nor a limiting factor to progress and innovation. 
Nanotechnology refers to the design, characterization, production and application of 
structures, devices and systems that have novel physical, chemical and biological 
properties, by controlling shape and size at the nanometer scale1 (Ebbesen and Jensen, 
2006). While this multidisciplinary scientific field is undergoing explosive development, it 
is also subject to many controversial debates among scientists, but not only2. The design 
                                                 
1 A nanometer (nm) is equal to one billionth of a meter (10-9 meter); formerly called millimicron (1/1000 
of a micron), the nano scale was denoted by the symbol mµ. As an illustration, the diameter of a red 
blood cell is roughly 1 000 nanometers (10-6 meter).       
2 A 3 days Conference on Risks associated with nanoparticles and nanomaterials was organised by the 
French National Institute on Research and Security (INRS) in April 2011, to discuss occupational health 
research issues. A public debate on Nanotechnologies was held in France from October 15th 2009 to 
February 24th 2010, organized by the National Commission on Public Debate (CNDP) the National 
official and independent body (full details are available from:  
http://www.debatpublicnano.org/index.html). 
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and assembly of sub microscopic devices called nanoparticles, which are 1 to 100 
nanometer in diameter (Kateb et al., 2011), are also the object of concern as to the safety of 
their use, and not only in the general public (Poland et al., 2008; Takagi et al., 2008; 
Genaidy et al., 2009; Murphy et al., 2011). Potential toxic effects of certain nanoproducts 
have legitimately conducted either the decision makers or the civil society to mobilise 
high level expert’s investigation not only in France (AFSSET, 2006, 2008; HCSP, 2009) but 
in most of the OECD member countries (Kaluza et al., 2008; DHHS-CDC-NIOSH, 2009; 
Ostiguy et al., 2010). In either case, among the multiple fields of application of 
nanotechnology, we believe that the development of nanomedicine, the application of 
nanotechnology for the diagnosis and treatment of human disease, should be oriented 
through the lenses of the above mentioned driving forces, and subsequently handled with 
special care. If any, this field of research, whether fundamental or applied, calls for the 
implementation of principles qualified as socially responsible (André, 2008). Charters, 
codes of conduct, guidelines and other such documents, are slowly adopted by 
institutions3 that promote Socially Responsible Research, introduced with various status 
(contractual or not) in their rules and procedures. 
Today, not a single country is exempt from the consequences of the early 21st century 
financial, economic and social crises which impact the capacities to pursue and meet the 
goals and objectives set globally, regionally or nationally for the health sector, both in terms 
of access to the health care system and improvement of the well being of the world 
population4. Funding issues, not only due to a trend towards aging of the world population, 
are among the challenges faced and choices have to be made among a variety of options. In 
our opinion, concentrating on the problems for which a sound alternative does not exist 
while privileging the most effective, efficient and sustainable measures probably represent 
the best strategic option. Decision makers, industrials, research institutions, non 
governmental organizations, many stakeholders claim that nanomedicine offers an 
excellent, innovative, and almost ideal solution to handle a lot of the medical problems faced 
by the world population, and at costs that can be contained (ETPN, 2006). Thus research in 
this discipline is evolving at a high speed. 
Given our diverse respective skills and competencies, we chose to develop a case study on 
this specific field of application of nanotechnology, with special integrated inputs from each 
individual of the multidisciplinary team (photo chemist conducting research in basic 
sciences, risk management specialist, public health medical specialist), in order to develop 
an interdisciplinary expertise open to large societal needs. 
                                                 
3 The European Charter for Researchers, edited in 2005 by the European Commission, has been adopted 
by many French research institutions, the National Centre for Scientific Research (CNRS) and the 
National Institute for Research in Agronomy (INRA) among others. Many other countries have also 
elaborated such document, Australia (Australian Code for Responsible Conduct of Research) and the 
USA (NIH Policy on instruction in the responsible conduct of research), among others. 
4 The 8 Millennium Development Goals (MDG), along with their quantified targets to be reached by 
2015 for the vast majority, were adopted at the United Nations Millennium Summit in September 2000. 
Three of them, MDG 4 (Reduce child mortality), MDG 5 (Improve mental health), and MDG 6 (Combat 
HIV/AIDS, malaria and other major diseases) address specifically health issues. According to the last 
report, released in July 2011, they are unlikely to be met, particularly in the most vulnerable 
populations. 
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We will first give an overview of nanomedicine in order to better situate research on 
photodynamic therapy among the various objects covered by this field of application of 
nanotechnology. This whole descriptive phase is done in the second section. After introducing 
the nanomedicine taxonomy, we will present the principal historical and technical elements, 
starting from the broad perspective of drug delivery systems and/or materials, in the sub-
section on biopharmaceutical, and then moving to a more detailed one, in the sub-section on 
photodynamic therapy. We will present photodynamic therapy more extensively, since the 
development of nanoparticles for use in this cancer treatment modality, the object of the 
research conducted by some of the authors5, is at the foundation of our case study.  
In the third section, centred on our case study, the design will be presented. The method and 
literature review will be introduced first. Then, in addition to a detailed presentation of the 
general framework, the research conducted by some of the authors, the content and 
implementation of a pilot survey that we conducted in June/July 2011 will be described. Our 
principal aim in doing that pilot survey was to dispose of first hand and shared information 
regarding the state of knowledge of our study object in the general educated public.  
The results of our pilot survey will be analyzed in section four. 
In the discussion, the following section, based on our professional experiences and using 
the main findings extracted from our pilot survey as illustrative arguments, we will 
highlight three management organizational modalities, the precautionary principle, 
knowledge management, and translational research, that we believe useful to implement 
in order to improve the risk management process in general, and the quality of our work, 
in particular. 
We will close with some lessons learned from these management modalities, a few broad 
recommendations, and an opening on ethical and regulatory issues.    
2. An overview of nanomedicine 
The concept of using nanotechnology in medical research and clinical practice holds great 
values and opens real perspectives for effective innovations in medical sciences (Sandhiya et 
al., 2009). Considering the broad spectrum of the series of technologies that can be used 
individually or in combination to make products and applications and to better understand 
science, efforts in classification have been initiated (Table 1). One way of characterizing 
nanotechnology is by utilizing the following four segments: tools, materials, devices & 
intelligent materials and machines. Those segments support the nanomedicine taxonomy 
developed by the Canadian Institutes of Health Research and the Canadian NanoBusiness 
Alliance (Gordon and Sagman, 2003). In a partial nanomedicine technologies taxonomy 
proposed in the beginning of this century, some of the most interesting and diverse current 
research projects within several of the 96 existing sub-categories were described (Freitas, 2005). 
The applications, which pertain to both medical and surgical diagnosis and therapeutic 
techniques, are as diverse as the development of nanoparticles for diagnostic and screening 
purposes, artificial receptors, DNA sequencing using nanopores, manufacture of unique drug 
                                                 
5 This refers to those of us from the Reactions and Chemical Engineering Laboratory of the National 
Center for Scientific Research. 
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delivery systems, gene therapy, enablement of tissue engineering, and, single-virus detection 
(Emerich, 2005). Indeed, nanostructures, whether still under development or already in use, 
have the potential to play a critical role in the future of medicine, as they can be carriers for 
drugs, genes, and imaging agents as well as targeting units (Kateb et al., 2011).  
The need for the development of a new framework, including regulations, procedures and 
mechanisms, adapted specifically to govern research in nanotechnology, thus 
nanomedicine, is as salient in Europe as in the United States. Heightened uncertainty 
regarding risks, fast-evolving science yielding complex and increasingly active materials, 
likelihood of research on vulnerable participants including cancer patients, and potential 
risks to others beyond the research participant are identified as relevant confluent factors in 
support of the need for an exceptional oversight beyond the existing Common Rules6 
supervised by either local or federal institutions such as the US Department of Health and 
Human Services, the Federal Drug Administration (FDA), notably its Centres in charge of 
overseeing drug, biologics, and device approval, the National Institutes of Health or the 
National Cancer Institute (Wolf and Jones, 2011). Concern regarding potential risks does not 
involve only the volunteers and candidates recruited to participate to clinical trials, but also 
workers employed in the manufacturing industries, as well as, during the fundamental 
research stage, scientists conducting experiments in public or private laboratories.  
At the European level also, the existing corpus of regulations needs to be progressively 
adapted to risk management specifically applicable to research in nanomedicine, even if 
enforcement will not necessarily be mandatory in each individual Member State. In France, 
Committees for the Protection of Citizen7, structures similar to those existing in the US, are 
in place and the supporting laws under review.  
Among the leading areas of research in nanomedicine summarized in the taxonomy (Table 
1), biopharmaceutics offers an array of applications, with numerous drugs either already 
commercialised or still subject to ongoing research programmes, whether in the public or 
private sectors. Within this research area, the development of new materials or systems to 
optimize the deliver of the therapeutic agents is a steady option. The development of 
nanoparticles for photodynamic therapy falls under this category. Thus, in the following 
two sub-sections, we will highlight historical and technical elements, first on 
biopharmaceutical, then on photodynamic therapy. 
2.1 Biopharmaceutics 
Liposomes, spherical vesicles that can be produced from natural nontoxic phospholipids 
and cholesterol, are made of a lipid bilayer surrounding a water core hosting the drug. The 
first studies to report the efficiency of liposomes as nanoparticles focused on the 
improvement of pharmacokinetics and bio-distribution of doxorubicin. Approved by the 
FDA on November 17th 1995, Doxorubicin HCI Liposome injection, an anti-neoplastic drug 
administrable intravenously, is probably the first nanoscale drug delivery materials that 
                                                 
6 Are identified as such the basic procedures existing since 1981 that rely mainly on Institutional Review 
Boards (IRB) and Data Safety Monitoring Boards or Committees.  
7 Comités de Protection des Personnes (CPP). 
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Nanotechnology segments & Nanomedicine Taxonomy 
(Source: Gordon and Sagman, 2003)8 
Tools Materials Devices 
Intelligent 
Materials & 
   Machines 
Microscopy 
Techniques & 
Instruments 
Raw 
Nanomaterials
Nanostructured 
Materials 
Nanotubes 
& 
Nano & Micro 
devices 
 
(no application 
expected soon) 
   Fullerenes   
      
Biopharmaceutics Biopharmaceutics  Understanding 
Basic Life 
Processes 
Drug Discovery Drug Delivery (systems and materials)  
Genetic testing* Drug Encapsulation    
Nanoscience in 
Life Sciences 
Ultra-sensitive 
Labelling & 
(Neurology, Ophthalmology)   
Detection 
Technologies 
 
Functional Drug Carriers 
(HIV/AIDS, Cancer) 
   
High Throughput 
Arrays & Multiple 
   
Analyses ("Lab on a 
chip" Technologies) 
      
Surgical Aids Implantable Materials  
Implantable 
Devices 
Implantab 
Materials 
Operating tools Tissue repair & replacement  
Assessment & 
Treatment 
Struct. Implant 
Mat. 
Smart Instruments 
(Surgical Tools & 
Implant coatings (e.g. for bone)  
Implantable 
sensors 
Smart Materials 
Optically Guided 
Surgery) 
  
(Blood level 
substance 
(Human 
   monitoring) enhancement) 
Surgical Robots 
[Joystick handles, 
control console & 
camera system] (Gall 
Bladder, Prostate, 
Colorectal, Esophageal
Tissue Regeneration Scaffolds 
(corneal, muscle, bladder & 
bone cells) 
 
Implantable 
medical devices 
with sensors to 
automatically 
deliver 
treatment 
(MEMS) 
 
& Gastric bypass)    
Diagnostic Tools Structural Implant Materials Sensory Aids  
Imaging Bone repair (Substitute & Cement) Retina Implants  
Nanoparticle Labels 
Bioresorbable Materials (Sutures & 
Orthopaedic Fixation Devices) 
(Degenerative 
diseases) 
 
Imaging Devices  
Cochlear 
Implants 
 
   (Hearing lost)  
* Measuring gene sequences (mutations) & expression levels (abundance) 
Table 1. A summary of Nanomedicine Taxonomy arranged according to Nanotechnology 
supporting segments 
                                                 
8Original table adapted from the Nanomedicine Taxonomy. Potential inaccuracy may have occurred in 
the proposed synthesis, and some items of the Nanomedicine Taxonomy may belong to more than the 
segments under which they appear. 
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 reached the market (Table 2).  Soon after during the same year, an antifungal, Amphotericin 
B Lipid Complex Injection, was approved. A significant number of drug products have been 
commercialized since then, including on platforms other than liposomal such as nanocrystal 
platforms, for various ill states (hypercholesterolemia, hypertriglyceridemia, anorexia etc.), 
and, in 2005, indicated in metastatic breast cancer, the first albumin nanoparticle was 
approved for human use (Wang and Thanou, 2010; Kateb et al., 2011).   
 
Platform Generic name Indication 
Route of 
Administration
Approval date 
Liposomal 
platforms 
Liposomal doxorubicin 
Ovarian and breast 
cancer 
intra venous 
(i.v.) 
17 November 95 
 
 
Daunorubicin citrate liposome 
injection 
Anti neoplastic i.v. 8 April 96 
 
Pegylated liposomal doxorubicin 
hydrochloride 
Ovarian and breast 
neoplasms 
Kaposi's Sarcoma 
Multiple myeloma 
i.v. 21 June 96* 
 Verteporfin for injection 
PDT for age-related 
macular 
degeneration 
 12 April 00 
 
Non-pegylated liposomal 
doxorubicin formulation 
Breast neoplasms i.v. 13 July 00* 
Other 
Platforms 
    
 Albumine taxol conjugate 
Metastatic breast 
cancer 
i.v. 7 January 05 
 
 
Dextran Ferumoxide injectable 
solution Superparamagnetic Iron 
Oxides Particles (SPIO) 
Magnetic 
Resonance Imaging 
(MRI) contrast 
agent for the liver 
i.v. 1 February 96 
 
Dextran coated iron oxide 
Ultra small Superparamagnetic 
Iron Oxides Particles (USPIO) 
MRI contrast agent i.v. 3 March 05 
Table 2. Some of the main nanoscale drug product approved for cancer treatment and 
diagnosis by the Federal Drug Administration in the USA (Zolnik and Sadrieh, 2009 as cited 
in Kateb et al., 2011) and by the European Medicines Agency* for use in the European Union 
Some key properties that make nanoscale liposome an excellent device for targeted drug 
delivery have been highlighted recently: they are biocompatible, biodegradable, not 
immunogenic, familiar to and mastered by the scientific community, have known 
pharmacokinetics, bio-distribution and metabolism. Therefore, from a toxicological stand 
point, they have advantages over other nanoproducts for medical pharmaceutical 
applications as well as consumer products in cosmetics and clean technology. 
Additionally, if introduced in excess, the liposomes may be destroyed by the 
macrophages, as seen in the natural course of their life cycle (Barenholz, 2010). 
Convincing, and that may also address the question of eliminating the product, if need be, 
to deal with an irreversible risk later identified. Thus, the research can be pursued until 
challenged by new discoveries.  
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This leads us to introduce reversibility, another important factor that we consider worth 
exploring, besides the concerns that we previously mentioned as leading our 
interdisciplinary expertise: prevention and precaution as the underlying humanistic driving 
forces presiding to the management of health risks at short, medium and long terms, and, 
strategic research development options which promote the most equitable, effective, 
efficient and sustainable fields. These factors will be touched upon throughout the following 
sections, and in particular in the discussion, with extensive developments on three 
complementary approaches to consider in risk management applied to our case study: the 
precautionary principle, knowledge translation and translational research.   
2.2 Photodynamic therapy 
Photodynamic therapy (PDT) is another important emerging research field for the 
development of nanoscale therapeutics (Bechet et al., 2008; Couleaud et al., 2010b; Vanderesse 
et al., 2011) that can optimize drug delivery of materials or systems. Photodynamic therapy 
involves the use of light, photosensitizers and oxygen. The photosensitizers, after excitation 
with light of an appropriate wavelength, can transfer their energy from their triplet excited 
state to neighboring oxygen molecules (Ortel et al., 2009). Reactive Oxygen Species (ROS) and 
singlet oxygen (1O2), which is commonly accepted to be the main cytotoxic species, are formed 
and lead to the destruction of cancer cells by both apoptosis and necrosis. PDT efficiency 
depends on the photosensitizer’s ability to produce ROS and 1O2, availability (Verhille et al., 
2010), light dose and photosensitizer concentration in the treated area. 
Used in dermatology to treat basal cell carcinomas as early as the beginning of last century, 
the application of this treatment modality stayed somehow confidential for quite a while, 
but PDT is now established as a clinical treatment modality for various diseases including 
cancer (Dougherty et al., 1998; Triesscheijn et al., 2006). PDT is currently being developed as 
a treatment for cancer of the esophagus, bronchi, and bladder, as well as for other non 
oncological applications, such as age-related macular degeneration (Agostinis et al., 2011), 
and is also used as a successful non-invasive therapeutic modality for treating cutaneous 
neoplasm. In France, research on PDT is developed within different laboratories from the 
National Centre for Scientific Research, with four main hubs located respectively in the 
Parisian Region (Evry, Orsay), Lille, Nancy and Toulouse. A partnership has been 
officialised for 4 years in 2007, with the establishment of a research network within the 
National Centre for Scientific Research’s Institute of Chemistry. Recognized by the acronym 
GDR9, the objective of the research network is to develop medicines that can be activated by 
light along with their therapeutic applications.  
The first photosensitizer to have received approval for use in PDT was porfimer sodium, 
authorized for the treatment of superficial bladder cancer in Canada in 1993, and later for 
early lung and advanced esophageal cancers in Netherlands and Japan (Triesscheijn et al., 
2006). Over the past decade, various types of photosensitizers have been developed in order 
to improve their properties (light absorption and diseased tissues selectivity) compared to 
the original first-generation ones (Table 3).  
                                                 
9 Groupement de Recherche (GDR) 3049 PHOTOMED Médicaments Photoactivables – 
Photochimiothérapies. More information available from the web site at:  
http://www.gdr-photomed.cict.fr/spip.php?rubrique1. 
www.intechopen.com
 
Risk Management for the Future – Theory and Cases 
 
92
Photosensitizer* Cancer types Chemical structure 
Excitation 
wavelength 
(nm) 
Approved 
First generation 
Porfimer sodium 
(Photofrin)(HPD) 
Bile duct, Bladder, 
Brain, Lung, 
Oesophagus, Ovaries 
Porphyrin 630 Yes 
Second generation 
ALA 
Bladder, Brain, 
Oesophagus, Skin 
Porphyrin precursor 
(protoporphyrin IX) 
635 Yes 
ALA esters Bladder, Skin 
Porphyrin precursor 
(protoporphyrin IX) 
635 Yes 
Temoporfin 
(Foscan)(mTHPC) 
Bile duct, Brain, Head 
and Neck, Lung, Skin 
Chlorin 652 Yes 
HPPH 
Head and neck, Lung, 
Oesophagus 
Chlorin 669  
SnEt2 (Purlytin) Breast, Skin Chlorin 660  
Mono-(L)-
aspartylchlorin-e6 
Talaporfin (LS11, 
MACE, NPe6) 
Brain, Colon, Liver Chlorin 660  
Ce6-PVP (Fotolon), 
Ce6 derivatives 
(radachlorin, 
photodithazine) 
Brain, 
Nasopharyngeal, 
Sarcoma 
Chlorin 660  
Silicon 
phtalocyanine 
Cutaneous T-cell 
lymphoma 
Phtalocyanine 675  
Padoporfin 
(Tookad) 
Prostate Bacteriochlorin 762  
Motexafin lutétium 
(Lutex) 
Breast Texaphyrin 732  
Third generation 
Verteporfin 
(liposomal 
formulation) 
Ophtalmic, Pancreas, 
Skin 
Chlorin 690 Yes 
Fourth generation (theranostic) 
  
Multifunctional 
nanoparticle 
  
*Abbreviations: HPD [Hematoporphyrin Derivative]; ALA [5-Aminolaevulinic Acid]; mTHPC [meta-
tetra (hydroxyphenyl)chlorin] ;  HPPH [2-(1-hexyloxyethyl)-2-devinyl-pyropheophorbide]; SnEt2 [tin 
ethyl etiopurpurin]; Ce6 [chlorin e6]; PVP [ polyvinylpyrrolidone] 
Table 3. Successive Generations of Photosensitizers used for the diagnostic or treatment of 
cancer with their main characteristics (Plaetzer et al., 2009; Agostinis et al., 2011)  
A second-generation of photosensitizers, such as chlorins and phthalocyanines, present 
better light absorption in the red part of the visible light spectrum, which commonly 
represent the therapeutic window because of the slightest absorption of endogenous tissues 
compounds in this area (mainly hemoglobin and water). Thousands of patients have already 
been treated with PDT using the first and second generation of photosensitizers for a variety 
of advanced neoplasms, and the treatment induced a great improvement in their quality of 
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life and lengthened their survival. Despite photophysical enhancements, the ability of these 
photosensitizers to discriminate between healthy cells and tumors remains low, leading to 
side effects such as photosensitivity in the presence of sunlight due to skin accumulation.  
A third generation of photosensitizers has been developed, based on a strategy of selective 
delivery of the drug into diseased tissues. They consist of second-generation photosensitizers 
combined with targeting units such as oligo-nucleotides, peptides or monoclonal antibodies 
(Chen et al., 2006), or photosensitizers encapsulated into nanoplatforms. Nanoparticles 
represent emerging photosensitizer carriers really promising for use in PDT. In bio-
nanotechnology, their development can overcome most of the shortcomings of classic 
photosensitizers. Potential advantages of nanoparticles are that a high “payload” can be 
delivered: they can transport hydrophobic drug in blood, their surface can be modified with 
functional group, they have a large volume of distribution and are generally taken up 
efficiently by cells, and, controlled release of drug is possible. It is commonly accepted that 
strategies used to deliver the photosensitizer specifically to diseased tissues using the target 
tissue receptors or antigens are termed “active”, whereas other formulations that enable 
parenteral administration and passive targeting are termed “passive”.  
Many nanoplatforms are being studied in the field of PDT (Figure 1), some of which are 
biodegradable (Figure 1a-e) and others not (Figure 1 f-l). The first nanodrug that reached the 
marked for use in PDT, approved in the USA by the FDA in April 2000, was a liposomal 
formulation, Verteporfin for injection, indicated for the treatment of predominantly classic 
subfoveal choroidal neovascularisation due to age-related macular degeneration, pathologic 
myopia or presumed ocular histoplasmosis (Table 2 and Figure 1e). 
Ln
LnLnAuNPAu Pu
Approximate
size (nm)
50 - 1000 > 100
30- 120501 1 - 10 5 - 50 30- 100
10 - 301 - 10
a) b) c) d) e)
f) g) h) i) j) k) l)
Approximate
size (nm)  
Biodegradable: a) dendrimers, b) polymeric micelles, c) polymeric capsules, d) polymeric nanospheres, 
e) liposomes, 
Non biodegradable: f) carbon nanotubes, g) gold nanoparticles, h) quantum dots, i) silica nanoparticles, 
j) zeolite, k) magnetic nanoparticles, l) up-converting nanoparticles  
Fig. 1. Main nanoplatforms used for cancer diagnosis and treatment in the field of PDT  
www.intechopen.com
 
Risk Management for the Future – Theory and Cases 
 
94
Among the many photosensitizing agents that are being elaborated, very few have made 
it to robust clinical trials. Although third generation photosensitizers have been widely 
described for selective targeting, very few have been evaluated for clinical applications 
as their in vivo selectivity was not high enough compared to the one demonstrated in 
vitro.  
However, the third generation sensitizers can potentially be grafted with targeting moieties 
and may encapsulate imaging agents and then lead to the fourth generation of 
photosensitizers. Theranostic nanoparticles can be considered as which can diagnose, 
deliver targeted therapy and monitor the response to therapy. 
Some key properties explain why nanoscale liposomes are an excellent material for targeted 
drug delivery (Barenholz, 2010) and the successful outcome of research using this approach, 
with the commercialization in November 1995, almost 17 years ago, of the first nanodrug 
developed on a liposomal platform, indicated for the treatment of cancer in gynecology. 
Many other nanodrugs have reached the market since, developed not only on liposomal 
platforms nor for treating cancers, such as verteporfin for injection, a product indicated for 
photodynamic therapy (PDT) in ophthalmology (Table 2).  
What factors, different in nature but similar by analogy to the key pharmacological factors 
identified and pushed forward for nanoscale liposomes, are likely to make research on nano 
PDT a sustainable and successful approach in the development of targeted drug delivery 
material or systems for the treatment of cancer? 
In order to try to indentify such factors and attempt to provide an answer to this question, 
we designed a case study to explore specific factors known to be crucial to risk management 
in complex settings involving multidisciplinary team work, complicated decision channels, 
fast-evolving highly technical new science and heightened uncertainty regarding potential 
risks but considerable potential human and financial benefits. We also designed a 
qualitative survey, to be conducted by questionnaire, addressed electronically to a selected 
population ranging from researchers specialized or not in the field of PDT to the educated 
social body, to investigate their perception of the research conducted in the field of 
Nanotechnology and Nanomedicine in general, and PDT in particular. The design of the 
case study is described in the next section, which starts with a presentation of the 
methodology used in constructing our interdisciplinary expertise, and the results of the pilot 
survey are analysed in section four.  
Considering the growing interest of the research community in nanomedicine, on one hand, 
and the complexity of nano PDT, a highly specialized field of research that involves many 
sectors and multiple scientific disciplines, on the other hand, it is difficult, if not impossible, 
for each individual researcher involved to apprehend completely the risk management 
process, in its full scope. Thus, in this chapter, we would like to investigate this further by 
identifying interventions that could be applied here to facilitate and improve the intake of 
risk management in the researchers’ preoccupation. In the course of the implementation of 
our interdisciplinary expertise, we have narrowed down the scope of our investigations to 
address exclusively, but in depth, three structured management interventions and 
modalities that have demonstrated their usefulness, which will be presented in the 
discussion (section five).  
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3. Design of the case study 
We start the description of the case study by introducing the method used and the literature 
that it is based on, before presenting the results of the pilot survey, in the following section 
(section 4). 
3.1 Method and literature review 
This interdisciplinary expertise was constructed using many iterative either bi or tri-
directional exchanges which can be summarized in three broad steps, mixing both bottom-
up and top-down approaches, moving from a large to more narrow perspective, inward 
and/or outward centre bound: 
1. Identification of the scientific object of the case-study and definition of its content. 
2. Mutual understanding of the each author’s potential contribution for integration: 
constrains, competencies and operational skills. 
3. Implementation by iterative construction. 
Starting from our respective knowledge base we first agreed on a common study object: the 
research on nano PDT conducted at the Reactions and Chemical Engineering Laboratory of 
the National Centre for Scientific Research10 located in Nancy. Although the experience was 
rejuvenating and stimulating, it entailed many challenged, some of which explain the limits 
of our work. The fact that the research on nano PDT involved other actors and ongoing 
scientific publications in a highly competitive field was a first obvious constrain that lead us 
to focus only on specific issues related to risk management. We also narrowed down the 
spectrum of our case study in order to obtain inputs from each individual of the 
multidisciplinary team: a photo-chemist conducting research in basic sciences and her post 
doctorate scholar, a risk management specialist and a public health medical specialist. We 
also expanded that spectrum, beyond a focus centred on individuals involved in that 
medical research domain, whether volunteers, patients or practitioners, in order to develop 
an interdisciplinary expertise open to large societal needs. Finally, among the many types of 
risks faced by research institutions, we concentrated mainly on internally driven hazard risk 
(i.e. health and safety issues), but also embraced, to a certain extend, both strategic and 
operational ones. 
Beyond agreement on a common study object, a common understanding of each others’ 
discipline was achieved in a progressive manner. Although the research on nano PDT 
conducted by some of us is at the foundation of our case study, our work also includes a 
qualitative survey. Our principal aim in doing so was to dispose of first hand and shared 
information regarding the state of knowledge of our study object in the general educated 
public. 
We made an extensive use of the Information and Communication Technology (ICT), 
various software (Microsoft Work and Excel for instance) in particular to generate the 
various tables and figures, and of the Internet. We exchanged material (texts, tables, figures, 
articles) via e-mail all through the course of our work’s development and used Google as a 
                                                 
10 Laboratoire Réactions et Génie des Procédés (LRGP) du Centre National de Recherche Scientifique 
(CNRS) - France. 
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tool to search for articles, retrieve full texts of certain publications and consulted various 
institutions’ website for information relevant to our case study. We held only one whole 
team physical meeting, but had many 2 or 3 team members work sessions, either in Paris or 
Nancy, or by telephone. 
The literature review does not present any particularity, in the sense that we used well 
known tools and methods, besides the fact that it was implemented in 2 specific and distinct 
steps. A specific bibliography is generated on Scopus and Medline, using various key words 
relevant to the research developed on nano PDT by some of the authors (PDT, nanoparticles, 
targeting, chemical grafting of fluorescent dyes, spectroscopy, interaction between light and 
living cells, etc). This is done on a regular base. Additional information is also added in an 
ongoing manner, during various continuing education operations such as scholarships, 
participation to national or international conferences and seminars or while tutoring post-
doctoral students. Similarly, a steady expertise is withheld by some of the team members in 
risk management and public health policy applied to nanotechnology and other medical 
fields.  Beside data banks such as those already mentioned (Scopus and Medline), Google 
Google scholar and Wikipedia are tools used on a regular base to keep abreast with 
knowledge development in the field of competencies. Update or skill development are also 
achieved using different continuing education media. 
The originality of our interdisciplinary expertise lies more on the procedure that we 
implemented. Since no relevant unique bibliography could be screened and shared by all, 
and considering the solid knowledge base detained individually, we provided each other 
with selected articles or information. Once the common scope and general direction were 
determined, we conducted additional literature research (Scopus, Medline, Google Scholar) 
for articles and institutional publications to complement our development on health and 
safety issues in a risk management perspective. The precautionary principle and knowledge 
translation were the first two concepts that appeared relevant to investigate in our search for 
an answer to our study question in the particular context of research on nano PDT. We 
expanded later and more briefly on translational research, as this new management 
paradigm is distinct from the others and holds interesting features which can also facilitate 
the risk management process and emphasize the sustainability of the research field. 
Today, working across sectors, fields and institutions is more and more frequent and slowly 
becoming the norm. However creating a common understanding of terms and concepts is 
difficult, because of the so many different linguistic styles. The limits of a purely 
disciplinary approach, which we consider improper to conduct relevant successful research 
in such complex fields, plead for interdisciplinarity in order to achieve a sound and robust 
risk management process.  
In the following two sub-sections, we will describe and analyze successively the two 
elements that constitute our case study: the research on nano PDT which is at its foundation 
and the qualitative survey, a pilot survey which constitutes a common baseline of 
information. 
3.2 General framework of the case study 
The strategy implemented at the Reactions and Chemical Engineering Laboratory (LRGP) of 
the National Centre for Scientific Research (CNRS), in close collaboration with the 
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Laboratory of Molecular Physical Chemistry (LCPM) and the Research Centre for Automatic 
Control – Centre Alexis Vautrin (CRAN-CAV), an anti cancer centre, both also located in 
Nancy, and the Physical Chemistry of Luminescent Materials Laboratory (LPCML), located 
in Lyon, consists in designing, characterizing and in vivo/in vitro testing new third and 
fourth generation photosensitizers to improve their selectivity for tumor vasculature and 
cells. So far, most of the endeavours in the development of tumor targeting-photosensitizers 
have focused on the targeting of markers over-expressed by tumor cells themselves, such as 
lectins (Distasio et al., 2005) or folic acid receptors (Gravier et al., 2008). Another promising 
strategy consisting in destroying endothelial cells lining angiogenic blood vessels may offer 
some advantages over the usual approach aimed at direct killing of tumor cells is also being 
developed. This vascular targeted PDT, designed by the acronym VTP for Vascular Targeted 
Photodynamic Therapy, could be proposed for a large number of vascularized tumors. 
Compared to conventional cancer cell-targeting approaches, targeting tumor vasculature is 
easier to access, more efficient in cancer cell killing, and has a lower likelihood of drug 
resistance development. This vascular effect can be potentiated either by modulating PDT 
scheduling or by designing photosensitizers that would localize primarily in the vascular 
compartment. For several years, the focus has been in developing photosensitizers coupled 
to vascular-targeting agents to target the neovasculature already formed (Tirand et al., 2006; 
Thomas et al., 2009). In order to improve PDT performance and more precisely the 
selectivity of the treatment, the potential of using nanoparticles is being investigated, 
particularly since 2008 (Bechet et al., 2008; Couleaud et al., 2010b), not only by the LRGP and 
its partners, but throughout Europe and in most of the OECD member countries. 
Thus, starting from no publication prior to 1994, the number of publications on the 
development of nanoparticles for use in PDT has shown a sharp growth rate between 2002 
and 2003 and is still increasing rapidly since 2006, reflecting the growing interest of the 
scientific community for the development of nano objects in the field of PDT (Figure 2). 
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Fig. 2. Evolution of the number of publications on Photodynamic Therapy using 
nanoparticles from 1994 to 2010 (analysis from Scopus) 
www.intechopen.com
 
Risk Management for the Future – Theory and Cases 
 
98
The French nano PDT hub located in Nancy develops, in collaboration with its partner in 
Lyon, multifunctional silica nanoparticles (Couleaud et al., 2011). These non-biodegradable 
nanoparticles seem to be promised to a long lasting career, as they satisfy all the 
requirements for an ideal targeted PDT. For instance, Hybrid gadolinium oxide 
nanoparticles have been suggested to be useful for Magnetic Resonance Imaging (MRI), for 
both diagnosis and treatment (Faure et al., 2008). Their small size (less than 50 nanometer in 
diameter), their silica shell that allows the covalent coupling of a photosensitizer, their 
polyethylene glycol grafting, make them an ideal nanoplatform for both imaging and 
Vascular Targeted Photodynamic therapy (VTP). Inhalation of crystalline silica is known to 
cause an inflammatory reaction and chronic exposure leads to lung fibrosis and can 
progress into the disease, silicosis. The mechanism by which particles are bound and 
internalized and the reason why particles are toxic is unclear. Amorphous silica has been 
considered to be a less toxic form, but this view is controversial. In order to inhibit tissue 
accumulation of the nanoparticles, one way is to promote the urinary excretion of the 
nanoparticles. This can be accomplished by increasing the solubility of the nanoparticles. In 
the multifunctional silica nanoparticles developed by the Nancy Hub Research Team & its 
partner in Lyon, polyethylene glycol grafting allows the covalent coupling of the peptide as 
well as a good solubility of the nanoparticles. By MRI in vivo in mice and ex vivo of the 
organs 24 hours post-intravenous injection, the elimination on the nanoparticles by renal 
excretion was demonstrated. More recently, the functionalization by peptides of such 
nanoparticle’s photophysical properties as well as cytotoxicity and in vitro photodynamic 
efficiency, were also reported, describing for the first time the molecular affinity of the 
functionalized silica nanoparticle to neuropilin-1 molecular target (Couleaud et al., 2011).  
Capitalizing on our respective past professional experiences and with the motivation to 
broaden our views for future developments, we have chosen to investigate some 
organizational issues that we consider crucial to take in account in order to forestall 
potential occupational, environmental and more broadly societal health risks emerging in 
the development of therapeutics using nanomaterials in PDT. 
One of the main focuses leading our study is “research and sustainability”, notably waste 
disposal, and, in this particular instance, the elimination of the nanoproduct, both from the 
body and in the environment. Thus, beyond the individual approach, the core of this work 
also concentrates on workers’ safety, and to a certain extent, exposure of close contacts and 
community effects. Indeed, since laboratory practices, waste, as well as human subject 
excretion of nanomaterials can raise environmental concern, analysis of environmental 
effects should also be examined (Wolf and Jones, 2011). 
3.3 The pilot survey 
The decision to conduct a qualitative survey rose from the need to dispose of first hand and 
shared information regarding the level of knowledge of our specific study object, 
nanomedicine and more precisely PDT using nanoparticles, in the educated public. It was 
designed to be conducted by questionnaire, addressed electronically to a selected 
population ranging from researchers specialized or not in the field of PDT to the educated 
social body, to investigate their perception of the research conducted in the field of 
nanomedicine in general, PDT in particular, and the associated potential health hazards 
along with the means of protection.  
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The questionnaire was elaborated with the intention to investigate different knowledge 
regarding medical research. A series of questions were organized in three sets that covered 
the following items:  
- five short questions relating to general information on nanomedicine and the pre-
requisite specific to the initiation of a clinical trial;  
- a broad and detailed table to fill, with the choice given to answer either yes, no or don’t 
know, to the same questions regarding the different phases in the development of a 
new product in medical research; the following points were investigated: 
interdisciplinary team work in practice, knowledge of versus compliance to the existing 
regulation on health & safety issues including their implementation in a cross sectoral 
and environment focused approach; 
- two additional questions pertaining to the special field of clinical research, regarding 
the transition from experiments on animals to trials in human and the implementation 
of the principle of the necessary informed consent of the participants.  
The target population was selected to cover an audience educated enough to be aware of the 
specific research field represented by nanomedicine. We initially aimed at two distinct 
groups: the general social body with approximately a master’s level of education, 
investigated via Non Governmental Organisations (NGOs), and a population of researchers, 
either practising or still in training.  
Four institutions were selected11:  
1. the “Académie Lorraine des Sciences”, a professional body with a total of 
approximately 300 members from multiple scientific backgrounds;  
2. the “INstitut des Sciences de l’Ingénierie et des Systémes (INSIS)”, one of the CNRS’s 
major actor of research acting in engineering sciences and covering roughly 10 000 
persons working in more than 150 laboratories all over the country; 
3. “Poursuivre”; 
4. the “Association de Veille et d'Information Civique sur les Enjeux des Nanosciences et 
des Nanotechnologies (AVICENN)”.  
We were provided with feedback from only the latter. 
The questionnaire was sent via e-mail to a representative of each institution, previously 
contacted, informed and sensitized of the strict deadline. Distribution was agreed to rest 
upon an intermediate within each of the selected institution, using internal mailing lists and 
the filled questionnaires were to be returned directly to the organizing team. A three weeks 
for response delay, going from June 10th to 30th 2011, was initially proposed to the 
participants, but the very low response rate in the course of implementation led to telephone 
contact with our correspondents and an additional five days bonus. The following biases 
were then identified: 
                                                 
11 The “Académie Lorraine des Sciences” (Academy for Science of the Lorraine Region) is a local 
regional institution, and the two NGO’s, “Poursuivre” and AVICENN (Surveillance and civic 
information on issues related to nanoscience and nanotechnology) have a national scope and 
audience. 
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- the institutions had transferred the questionnaire on a hierarchical mode, and, in most 
cases, the responsible had delegated the answer to the individual in their team they 
judged the most competent on the central theme of our survey; 
- similarly, and in particular in the case of the NGOs, our correspondents informed us 
that their activities being extremely far from the subject of PDT, they did not feel 
legitimate to answer the questionnaire. 
Although the total number of individual who actually received the questionnaire to fill is 
unclear, the response rate, with 21 questionnaires returned filled, among which 14 from the 
Nancy hub, was obviously certainly very low. This observation is particularly striking for 
the intended investigation of the general social body, as only one representative of 
AVICENN, identified as the focal point by the institution, provided us with one duly 
completed and extensively commented questionnaire that reflected the NGO’s standpoint. 
4. Results of the pilot survey 
In fact, the questionnaire covers a wide sample of disciplinary and applied scientific fields: 
research, Research and Development (R&D), experiments on animals and clinical research 
in human, doctor-patient relationship, ethical and regulatory issues relating to social 
responsibility, etc. It was conceived to collect first hand and shared information on the 
competencies of different actors or social groups on our specific field of study: 
photodynamic therapy using nanoparticles in cancer therapy. The previously described 
limitations and biases, notably in the recruitment of the target population (screening and 
casting), make our pilot survey totally unsuited to be representative of the expression of an 
educated population’s opinion, but still useful for our initial and immediate purpose. 
Moreover, this could also be an interesting preliminary and very instructive phase to 
determine feasibility of a similar survey on a larger scale. 
In summary, our survey, implemented from June 10th to July 5th 2011, provided note worthy 
elements of information that served our need to better situate the use of nanoparticles in 
PDT as a field of relevant clinical research. 
1. Respondents are rather competent on the central theme, master quite well the clinical 
medical issues, and in particular the classical known difficulties specific to moving from 
research to the application of the results in current practice (i.e. knowledge translation 
and translational research). 
2. Association between creativity and interdisciplinary approach is subject to a real 
debate, partly due to lack in fruitful interactions between the many scientific fields 
and insufficient funding; however, when existing, the interdisciplinary mode of 
action is centred on the specific application, without an analysis of the related other 
aspects (i.e. health and safety issues, risk prevention, regulatory and ethical 
considerations). 
3. Precautionary approach indispensable to conducting clinical research seems completely 
unknown, in particular the health & safety issues specific to each of the phases in a 
product’s development starting from basic research is not the object of much attention 
from the various categories of responding professionals (researchers, technicians, 
maintenance, transport and cleaning personals). The discourse refers only to the 
existence of regulation without explicit mention of risk management in this context of 
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uncertainties; the precautionary principle for instance is not highlighted and priority 
seems to be given “only” to the scientific production attached to research. This 
comment does not apply to the answer provided by AVICENN, since the organisation 
is grounded on a social mission to inform on the risks related to nanosciences and 
nanotechnology, and feeds its legitimacy on the surveillance of their applications, thus 
on short and long term effects in human and the environment. 
4. As a whole, risks identified are centred on those incurred by patients who are 
concerned with the intake of nanodrugs in clinical research, and in particular 
bioaccumulation, while hazards which may occur in hospital personnel who attend 
their needs are not mentioned. The same observation applies when it comes to the 
elimination of those substances which may cause damage to the environment, and the 
waste generated is not the object of expressed concern. Hence, life cycle analysis is an 
element that should be induced in the various professional’s preoccupations. 
5. Doctor-patient relationship in their interactions is well described, as well the role of the 
doctor in relation to his patients. 
6. Interesting comments are made regarding commercialisation of new products after 
approval by the relevant authorities, but they are situated outside of the scope of our 
pilot project. They probably translate a context effect with the present debate occurring 
in France. 
Concerning specifically health and safety preventive measures at the workplace and the 
question investigating knowledge of versus compliance to them, besides the fact that in most 
instance (70%) respondents either declared a lack of knowledge or did not pronounce 
themselves outside of their own area of practice, some interesting remarks made can be 
highlighted and commented: 
1. The absence of a real culture of prevention in university settings, probably related to the 
absence of control by the relevant authority, along with a pressure to deliver 
immediately, which contrasts with the industrial world where risk prevention is 
rigorously handled, apart probably within subcontracting companies. 
2. The need to upgrade the health and safety equipment and installations in the 
universities to render them appropriate to safe working conditions, leading responsible 
management to use some of their project funding toward this end, an honourable 
decision but nevertheless a form of misappropriation of funds. 
3. The question of the information of the personnel, and more broadly of the citizens vis à 
vis the traditional dialectic of a priori criticism of the precautionary principle is raised. 
Viewed as a bridle to innovation and the freedom of entrepreneurship by some, the 
application of the precautionary principle can be an interesting economic and social 
development tool to avoid health crisis, such as the asbestosis one which negative 
effects are well known today. Moreover, it can sustain the public’s demand of an As 
Low As Reasonably Achievable (ALARA) type of leadership (Manigat et al., 2010).   
4. The notion of independence of the experts in general, and of the scientists in particular, 
when conducting safety studies, imperious in order for the results to be delivered 
without pressure to major or minor risks, pleading for funding from independent 
institutions. 
However, no conclusion in term of weight of the above mentioned remarks and comments 
can be reasonably made, as a good amount of respondents (30%) reported difficulty in 
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understanding the questions that they qualified either unclear or expressed in a too 
complicated format, and skipped the question. Among those, around 50% expressed their 
reasons, which can be summarized by the following two explanations: the questionnaire 
was too long and the time announced to fill it was inadequate, and, the fields investigated 
were too broad and too distant from their own work environment.   
5. Discussion 
Whether political, administrative, legal, industrial, scientific or technical, public or private, 
any kind of organisation claims legitimately to aim at meeting their immediate, intermediate 
or long-term, more distant objectives. The key element for success is obviously a realistic 
planning were objectives are set taking in account the required material and human 
resources. Whether internally or externally driven, four types of generic risks can threaten 
the achievement of the goals and objective of an organisation: financial, operational, 
strategic and hazards (IRM, 2002). 
Risk management, which can be defined as the set of individual or institutional response 
to the analysis and assessment of risks, including decisions to reduce or control risks 
(Ebbesen and Jensen, 2006), covers distinct realities according to the area involved 
(enterprise, industry, project, technology etc.). However, diverse initiatives have 
successfully conducted to a comprehensive approach and an internationally recognized 
level of standardization12. Risk management protects and adds value to the organisation 
and its stakeholders through supporting the organisation’s objectives by different means, 
and notably: i) providing a framework that enables future activity to take place in a 
consistent and controlled manner, ii) improving decision making, planning and 
prioritisation, including in the allocation of material and human resources, iii) reducing 
volatility in the non essential areas, iv) protecting and enhancing assets and the 
organization’s image, v) developing and supporting the knowledge base, and, optimizing 
operational efficiency (IRM, 2002). 
Risk treatment, inclusive of the risk management process (Figure 3), comprises risk 
control/mitigation as its major element, but extends further to risk avoidance, risk transfer, 
risk financing etc. However, the standard states specifically that compliance with laws and 
regulations is not an option. 
In the following three sub-sections, we will discuss concepts that we believe useful to take in 
account in order to improve the risk management process, in general, and the quality of our 
work, in particular. The precautionary principle and knowledge translation will be 
highlighted first and extensively, as they immediately appeared relevant to investigate in 
our search for an answer to our study question. We will also expand on translational 
research, as this new management paradigm, distinct from the others, also holds interesting 
features which can contribute to make research on nano PDT a sustainable and successful 
approach in the development of targeted drug delivery material or systems for the 
treatment of cancer. 
                                                 
12 ISO/IEC Guide 73:2009. Risk management – Vocabulary, and, ISO/DIS 31000 (2009). Risk 
management – principles and guidelines on implementation, among others. 
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Fig. 3. The Risk Management Process (IRM, 2002)  
5.1 The precautionary principle 
Like scientists, who include elements of caution in the course of the assessment of scientific 
data, decision-makers are faced with similar issues, and can rely on the precautionary 
principle in a structured approach to risk management when shaping, accenting then 
releasing their decision. Although the two processes do resemble, they differ in the sense 
that the recourse to the precautionary principle is a particularly relevant strategy to the 
management of risk when potential dangerous and irreversible effects have been identified, 
but their scientific estimation holds a certain level of uncertainty. The decisions made using 
this strategic option can take many forms and does not necessarily have to be a binding legal 
measure. However, it should be transparent and involve, as early as possible and to a 
reasonable extent, all interested parties (CEC, 2000). In that respect, the recourse to public 
consultations, a practice that the Information and Communication Technology (ICT) has 
considerably facilitated, is spreading rapidly, and in particular within the European 
Commission. 
In France, the principle was introduced in the country’s legal regulation by the law related 
to the reinforcement of the environment’s protection dated February 2nd 1995, often referred 
to as “la Loi Barnier”, which expresses the way to explore systems where risks are not 
mastered. Hence, in its article L200-1, the Rural Code stipulates: The precautionary 
principle, according to which the absence of certainty, given the state of scientific and 
technical knowledge, should not delay the adoption of effective and proportionate measures 
to prevent a risk of serious and irreversible environmental damage at an economically 
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acceptable cost. When applied, it is clearly a means to manage uncertainties and in no way a 
means of abstention. This new framework developed to implement action is of particular 
relevance in our contemporary world where innovation is intensively generated, as it leaves 
room to adapt to change.  
At the supra national level, the most recent consensus rely on the February 2000 
Communication from the Commission (CEC, 2000), in which all of the major components of 
the precautionary principle agreed on are specified, and in particular the need for decision 
makers to be aware of uncertainty attached to the result of the evaluation of the available 
scientific information and the eminently political responsibility for judging what is an 
acceptable level of risk for society. Gaps in knowledge and scientific uncertainty highlighted 
after the evaluation of a potential hazard are among the triggering factors that can lead to 
the recourse to the precautionary principle. 
It is important to point that the general concept of risk management is quite similar to the 
precautionary principle, although it applies to a context of a more established certainty. The 
recourse to the precautionary principle, particularly relevant when facing a severe and 
irreversible potential hazard, can intervene after the risk assessment sequence of the risk 
management process.  
The implementation of the precautionary principle in medical research and public health 
also calls to revisit the current causal inference methodologies (Kopelman et al., 2004; Weed, 
2004) and to refocus on many fundamental ethical principles and values (Jardine et al., 2003). 
The principle is of extensive use also in the USA and Canada, by both Governments and 
Non Governmental Organizations, professional bodies, and the civil society, as illustrated 
by the following examples: the Canadian Environmental Act 1999 that came into force on 
March 31st 2000; the introduction of the precautionary principle by New York State and San 
Francisco City & County in their respective regulations in March 2003; the Wingspread 
Statement on the Precautionary Principle released by a group of scientists, philosophers, 
lawyers and environmental activists on January 20th 1998 to resume after a three days 
conference; or the American Public Health Association’s resolution on the Precautionary 
Principle and Children’s Health dated November 15th 2000.  
Therefore, crucial to the theme of our work, our subsequent development will be centred on 
management and organizational modalities that have rendered their usefulness: knowledge 
translation and translational research. 
5.2 Knowledge translation 
Lack of knowledge, whether poor level of information or apparent inadequate use of 
knowledge regarding health and safety at the work place, regardless of the product in 
development’s stage and environment (i.e. type of laboratory), was mentioned in a good 
proportion of the educated populations’ responses to our questionnaire. Thus, considering 
the main characteristics attached to the subject of nanodrugs for PDT in cancer therapy13, it 
                                                 
13 One of the most rapidly growing branch of science and fairly new field of research – nanomedicine – 
but using an old but not frequently applied technology - PDT, numerous actors and stake holders 
involved, real controversies debated on health risks with sister technologies like carbon nanotubes, 
incredible economical weight voiced by industrials as to potential benefits challenged by NGO’s as to 
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seems more than relevant, in today’s health economic-aware environment, to question the 
knowledge translation process which provides scientific methods for closing the knowledge 
to action gap and identify the inherent barriers and facilitators (Straus et al., 2009a). 
Knowledge translation is defined as a dynamic and iterative process that includes synthesis, 
dissemination, exchange and ethically-sound application of knowledge to accelerate the 
capture of the benefits of research through improved health, more effective services and 
products, and to strengthen the health care system. This process takes place within a 
complex system of interactions among researchers and users that may vary in intensity, 
complexity and level of engagement depending on the nature of the research and the 
findings as well as the needs of the particular knowledge user (CIHR, 2004). 
We adopted the knowledge to action process developed in Canada, as the guiding 
overarching framework to identify potential areas of possible usefulness for the 
improvement of such an intervention (Figure 4). 
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Fig. 4. Knowledge to action process (Graham et al., 2006)  
                                                                                                                            
long term potential effects detrimental to man, endless amount of available information, huge already 
existing market applications and developments. 
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In the course of the knowledge translation process development, whether during the 
creating or applying phases, some steps are more prone than others to allow identification 
of knowledge to action gaps, barriers or facilitators, which, when assessed at an early stage, 
can successfully lead to find suitable solutions. Considering the knowledge issues 
commonly identified in health and security studies, and also observed in the results of our 
pilot survey, it is worth stressing that knowledge needs and knowledge use should be the 
object of special focus, and carefully addressed.  
The identification of knowledge to action gaps can occur anytime throughout the course of 
the knowledge translation development, either when refining distilling and tailoring 
knowledge to the needs of end-users during the knowledge funnel (i.e. inquiry, synthesis, 
and generation of user friendly knowledge tools and products), or when applying 
knowledge during the action cycle while assessing barriers & facilitators to knowledge use 
or developing mechanisms to sustain ongoing knowledge use (Straus et al., 2009a). 
It has been established that gaps between research and practice may result from interacting 
factors such as limited time and resources of practitioners, insufficient training, lack of 
feedback and incentives for use of evidence-based practices, inadequate infrastructure and 
systems organisation to support translation. More recently, the assumption that 
effectiveness research (intended to measure the impact of an intervention on the target 
population) naturally and logically follows from successful efficacy research (which purpose 
is to establish a causal link between and intervention and its outcome), has been challenged 
in health promotion research, leading to highlighting a disconnection inherent to their very 
distinct designs and purposes. The moderating factors, that limit robustness across settings, 
populations, and interventions staff, need to be addresses in efficacy studies (Glasgow et al., 
2003). 
To sum up, we want to highlight the following remarks:  
1. Underuse or overuse of evidence with critical impacts have often been reported, 
making monitoring of knowledge use a fundamental issue, considering the different 
types that may be involved; the appropriate method to close or lessen gaps in 
knowledge use will vary whether dealing with conceptual (to change the levels of 
knowledge, understanding and attitudes), instrumental (to change behaviour or 
practice) or strategic (as ammunition in the attainment of power or profit) knowledge 
use (Straus et al., 2009a; Manigat et al., 2010). 
2. Assessing barriers and facilitators to the implementation of shared decision making is 
crucial, since barriers and facilitators are the salient beliefs of self efficacy, the most 
important determinant of behavior change after intention, on one hand, and, 
considering the fact that a given factor can be perceived as both a barrier or a facilitator, 
on the other hand (Straus et al., 2009a). 
3. Interest in sustainability of knowledge use is quite recent (Graham et al., 2006), 
nevertheless, the consideration of sustainability, which includes discussion of 
budgetary and human resources, should occur early in the process (Straus et al., 2009a). 
4. Lack of knowledge, also identified in our survey concerning health and security issues, 
is, with variability, one of the two generic sources of uncertainty; it can be either 
structural or due to unreliability, and in that second instance potentially measurable 
(Van Asset, 2000, as cited by Hoppe, 2009; Van Asset et al., 2002). 
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5. Uncertainty in knowledge is now an established triggering factor for the application of 
the precautionary principle (CEC, 2000). 
6. When people are given more freedom to get involved, they more actively engage in 
finding creative solutions to routine problems and implementing them (Straus et al., 
2009a). 
Ultimately, and consistent with the vision for knowledge management promoted by the 
Canadian Institute of Health Research (CIHR), the development of a systematic, integrated 
approach to accelerate optimal use of the best available research evidence in the interest of 
health would be particularly useful here. Furthermore, as often reported and also evidenced 
in the analysis of the information retrieved in our survey, it appears that a real margin of 
improvement does exists, since gaps in knowledge remain in the course of the 
implementation in highly interdisciplinary research in nanomedicine. The four comments 
aforementioned concerning specifically health and security preventive measures at the 
workplace are valid beyond biomedical research and the field of nanomedicine. Pushed 
forward with the recent controversies, still ongoing, regarding nanosciences and 
nanotechnology, they unfortunately reflect the general “traditional” and prevailing situation 
which critically calls for reconsideration. A deep reflexion could be advantageously 
developed, centred on the following: a reasoned exploration for the frame of application of 
the precautionary principle for nanodrugs and nanomedicine; communication on the 
innovations in the field; the interrelations between the product and technique conceivers 
and users; and, in order to prevent potential environmental hazards, the life cycle analysis, 
the development of research on processes to eliminate waste or recycle the material.  
5.3 Translational research 
Translational Research also aims to bring health information and discoveries to the public to 
improve well being and health.  Although, the term may mean different things to different 
people, it was initially described as comprised of two areas of translation (Figure 6): the 
process of applying discoveries generated during research in the laboratory and in 
preclinical studies to the development of trials and studies in humans and vice versa – or 
from bench to bedside and back (T1 translation), on one hand, and, research aimed at 
enhancing the adoption of best practice in the community and back – or from research into 
practice (T2 translation). Two additional translations were later identified to better reflect 
the complexity of the second component of the translational research paradigm: moving 
research finding into the daily care of patients (T3), and moving scientific knowledge into 
the public sector and thereby changing people’s everyday life (T4) (Woolf, 2008; Kon, 2008). 
Improving the funding balance within translational research, between “bench to bedside 
(T1)” and “research into practice (T2)”, the latter often overshadowed by the primer 
notably in the United States, was shown to be crucial at a time when experts warn of the 
fragmented health care system and the huge disparities in access and quality of care. 
Poverty matters as much as proteomics in understanding disease, even though the 
scientific discoveries and spectacular new devices are more fascinating to the public and 
more lucrative to the industry. Additionally, for many diseases, T2 could save more lives 
than T1 as, for example, greater fidelity in administering aspirin to eligible patients might 
prevent more strokes than developing more potent antiplatelet agents (Woolf, 2008). 
Under this translational research paradigm, (i.e. avoiding to neglect historically less 
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glamorous components than bench research which are prone to dramatically improve 
public health and decrease cost), there will be more funding and consequently more 
recognition for such work (Kon, 2008).     
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Fig. 5. The Continuum of Biomedical Research (UTSUMC, 2011) 
The research on PDT using nanoparticles developed at the Reactions and Chemical 
Engineering Laboratory of the National Centre for Scientific Research is also implemented 
within a network of laboratories and could benefit from implementing the concept.  
6. Closure and future work 
Building on the study of 14 past cases, drawn as far as in 1896, related to hazards that 
caused damage to humans and the environment and for which early warnings where 
available, the European Environmental Agency (EEA, 2001) produced a report that 
illustrates the relevance of the precautionary principle’s implementation. The following 
twelve late lessons learnt where highlighted from this historical analysis: 
1. Acknowledge and respond to ignorance, as well as uncertainty and risk, in technology 
appraisal and policy-making. 
2. Provide adequate long term environmental and health monitoring and research into 
early warnings. 
3. Identify and work to reduce blind spots and gaps in scientific knowledge. 
4. Identify and reduce interdisciplinary obstacles to learning. 
5. Ensure that real world conditions are adequately accounted for in regulatory appraisal. 
6. Systematically scrutinize the claimed justifications and benefits alongside the potential 
risks. 
7. Evaluate a range of alternative options for meeting needs alongside the option under 
appraisal, and promote more robust, diverse and adaptable technologies so as to 
minimize the costs of surprises and maximise the benefits of innovation. 
8. Ensure use of lay and local knowledge as well as relevant specialist expertise in the 
appraisal. 
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9. Take full account of the assumptions and values of different groups. 
10. Maintain the regulatory independence of interested parties while retaining an inclusive 
approach to information and opinion gathering. 
11. Identify and reduce institutional obstacles to learning and action. 
12. Avoid paralysis by analysis by acting to reduce potential harm when there is reasonable 
ground for concern.       
They all appear relevant to be taken in account in our subject of study with two central 
themes also quite consistent with the conclusive analysis of our pilot survey: knowledge 
issues in a scientific field were risks are identified but not yet fully evaluated thus 
withholding uncertainties, and, obstacles to learning in interdisciplinary settings.  
The heightened possible risks widely described for certain nanomaterials in recent 
publications (Poland et al., 2008; Takagi et al., 2008; Genaidy et al., 2009; Murphy et al., 2011), 
the multiple sources of uncertainty, either primary due to variability or secondary in 
relation to limited knowledge, the absence of a robust common and universally accepted 
terminology, the ongoing debates to agree on appropriate regulation, are so many reasons 
that makes it legitimate to refer to the precautionary principles in the course of the decision 
making process when dealing with particles, materials and devices in nanomedicine. 
Knowledge management is crucial, so referring to knowledge translation should also 
carefully be considered in that context of uncertainties and controversial points of view, 
where knowledge gaps are definitely known to exist. The systematic and full use of the 
knowledge to action process, funnel and action cycle, may offer a model on which research 
institutions should consider relying, either for internal evaluation (e.g. when monitoring 
knowledge use) or during external audits (e.g. for evaluation of outcomes). Although 
sustaining knowledge use appears as the last of the 7 steps in the action cycle (Figure 5), 
consideration of sustainability, which include discussion on budgetary and human 
resources, should occurs early in the process (Straus et al., 2009a).  
However, awareness should exist on the fact that a successful implementation of knowledge 
translation is also a daunting task, considering the challenges to be faced, and in particular 
the lack of knowledge management and infrastructure, such as the huge volume of research 
evidence currently produced, access to research evidence, time to read and skills to 
appraise, understand and apply research evidence. Other challenges identified operate at 
many other different levels, including the health care system (e.g. financial disincentives), 
the health care organization (e.g. lack of equipment or personnel), the health care teams and 
individual professional, and also the patient (Straus et al., 2009b). Although the strategy may 
not have been extensively studied in the health care research sector, the use of either 
information specialists (Wilkinson et al., 2009) or knowledge brokering (Oldham and 
McLean, 1997; Lomas, 2007; Dobbins et al., 2009), as seen in clinical nursing practice (Kent et 
al., 2009), could be an interesting strategy to implement after further proper assessment of 
possible added value, in order to enhance knowledge translation. 
Since, when people are given more freedom to get involved, they more actively engage in 
finding creative solutions to routine problems and implementing them (Straus et al., 2009a), 
management style is also important and the stewardship theory of management, developed 
as a counter strategy to agency theory in 1997 (Olson, 2008), should be explored. Beyond the 
afore mentioned need for a relevant level of material and human resources, indeed the five 
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components of the management philosophy of the stewardship theory of management (i.e. 
performance enhancement, long-term orientation, empowerment, open communication & 
trusting relationship) could be inspiring to reduce interdisciplinary obstacles to learning as 
well as institutional obstacles to learning and action. 
Although risk management is increasingly recognized as being concerned with both positive 
and negative aspects of risks, in the safety field, risk management’s focus should be on 
prevention and mitigation of harm, as it is generally recognized that in that given field, 
consequences are only negative (IRM, 2002). Compared to research in techno-sciences, 
scientists who initiate research in the biomedical field have obviously integrated ethical 
issues in their processes (Couleaud et al., 2010a). Among the explanations, we retain the 
consequences of some major health crisis such as the use of thalidomide and the cancer of 
the uterus later induced in the offspring or the asbestos induced mesothelioma in factory or 
construction industry workers. Today, risk analysis seems inclusive of the culture of most 
medical scientists.  
The ethical considerations to take in account when addressing some technologies developed 
for applications in nanomedicine have been examined, notably for nanosurgery, tissue 
engineering, diagnostics and targeted drug delivery (Ebbesen and Jensen, 2006). Although 
ethical considerations to take in account when developing research in the field of 
nanomedicine are more complex, the knowledge base acquired in the field of bioethics 
seems sound enough, and the recourse to the four principles of Beauchamp and Childress’ 
theory  - doing Good (Beneficence), avoiding harm (Non-Maleficience), respect of autonomy 
(Autonomy Protection) and justice (Protection of Equity/Justice) -  a set of values commonly 
used today in ethical analyses (Ebbesen and Jensen, 2006; Westerholm, 2010), something to 
build on. The increasing weight of cancer in the global mortality and morbidity legitimates 
to search for new drugs and the discovery of new modes of treatment. However, research 
protocols applied on vulnerable populations have also obvious ethical limitations and also 
call for a thorough oversight. The need for interdisciplinary research on the ethical, legal 
and social implication of nanomedicine and enhanced information exchange, particularly on 
toxicity studies and informed consent procedure with regard to safety, has been underlined 
by the European Group on Ethics in Science and New Technologies to the European 
Commission (EGESNT/EC, 2007). The group has also argued that as far as public 
participation is concerned, transparency, including openness about uncertainties and 
knowledge gaps, is essential to ensure public trust in nanotechnology. Moreover, the group 
has stressed that in prospective technology assessment, consideration of social effects should 
expand to the developing countries. Indeed we agree, as we believe in global adaptation of 
new technologies to the human species and not in the reverse paradigm (Manigat et al., 
2010). A large interdisciplinary scientific debate has to be opened to agree on boundaries 
and limits, notably to human enhancement, include the decision makers to set strategic 
orientations and expand to the civil society.  
While ethical considerations should have always been consubstantial with the practice of 
medicine (Hippocrates’s Oath, Code of deontology), the need for legislative measures has 
emerged partly with the growing complexity of medical practice and research in humans, 
and probably more strongly with the history of past events such as the Tuskegee syphilis 
experiment in the US (Emanuel and Menikoff, 2011). The urge to adapt the legal framework 
to the challenges of nanomedicine, maybe even on a regular base, is real, and the debate on 
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the most appropriate reform is an ongoing process in the USA as well as in France and 
within the European Commission Member States. The call for the development of 
mandatory nanospecific regulation seems highly legitimate since most existing laws and 
regulations focus on cleaning up and controlling damage rather than preventing it14, and is 
consistent with the claim from the industrials that nanotechnologies are novel technologies. 
Since the risk management process clearly specifies that compliance with the laws and 
regulations is not an option, needless to stress that the rules must be carefully conceived in 
order to be also applicable, and achieving that could be a daunting and lengthy process.  
Additionally, monitoring of the insurance industry’s policies is worth investigating and can 
provide useful inputs, as risk treatment can be dealt with using risk financing and insurers 
do not manage risk coverage haphazardly. 
The implementation of this interdisciplinary expertise was a unique experience from 
which we can highlight the following elements as key messages: 
 The limits of a purely disciplinary approach, which we consider improper to conduct 
relevant successful research in such complex fields, considering the multiplicity of the 
knowledge gaps and other issues that are at stake and jeopardize a sound risk 
management process.  
 Although the pilot survey was developed for a precise and limited purpose, it could 
serve as the first step - the feasibility phase – of a qualitative study for a larger research 
project, if proper funding can be obtained. 
 Lessons learnt from the precautionary principle, applied in risk management of many 
other instances, could be food for though in the development of nano PDT as a 
relevant and sustainable research field in medicine. 
 Translational research, another new management paradigm, should also be explored.  
 Other recommendations are expressed (e.g. the use of information specialists or 
knowledge brokering, the shift to a stewardship style of management), addressed to 
the decision makers, and it is up to the relevant authority to decide whether or not they 
want to implement them.    
 Moreover, future work can also usefully be conducted, oriented in the two following 
sectoral directions that represent real openings: ethical and regulatory issues.   
“One hopes that our society will be able to muster the collective financial and moral courage to allow 
such extraordinarily powerful medicine to be deployed for human betterment, with due regard to 
essential ethical considerations.” Robert Freitas 
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